NasdaqGS - Nasdaq Real Time Price USD

Amgen Inc. (AMGN)

300.19 -5.65 (-1.85%)
At close: 4:00 PM EDT
300.00 -0.19 (-0.06%)
After hours: 6:54 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
29,532,000.00
28,190,000.00
26,323,000.00
25,979,000.00
25,424,000.00
--
Cost of Revenue
9,931,000.00
8,451,000.00
6,406,000.00
6,454,000.00
6,159,000.00
--
Gross Profit
19,601,000.00
19,739,000.00
19,917,000.00
19,525,000.00
19,265,000.00
--
Operating Expense
12,634,000.00
11,842,000.00
10,351,000.00
10,381,000.00
10,126,000.00
--
Operating Income
6,967,000.00
7,897,000.00
9,566,000.00
9,144,000.00
9,139,000.00
--
Net Non Operating Interest Income Expense
-3,156,000.00
-2,875,000.00
-1,406,000.00
-1,197,000.00
-1,262,000.00
--
Other Income Expense
534,000.00
2,833,000.00
-814,000.00
-1,246,000.00
256,000.00
--
Pretax Income
4,345,000.00
7,855,000.00
7,346,000.00
6,701,000.00
8,133,000.00
--
Tax Provision
582,000.00
1,138,000.00
794,000.00
808,000.00
869,000.00
--
Net Income Common Stockholders
3,763,000.00
6,717,000.00
6,552,000.00
5,893,000.00
7,264,000.00
--
Diluted NI Available to Com Stockholders
3,763,000.00
6,717,000.00
6,552,000.00
5,893,000.00
7,264,000.00
--
Basic EPS
7.03
12.56
12.18
10.34
12.40
--
Diluted EPS
7.00
12.49
12.11
10.28
12.31
--
Basic Average Shares
535,500.00
535,000.00
538,000.00
570,000.00
586,000.00
--
Diluted Average Shares
537,500.00
538,000.00
541,000.00
573,000.00
590,000.00
--
Total Operating Income as Reported
6,967,000.00
7,897,000.00
9,566,000.00
7,639,000.00
9,139,000.00
--
Total Expenses
22,565,000.00
20,293,000.00
16,757,000.00
16,835,000.00
16,285,000.00
--
Net Income from Continuing & Discontinued Operation
3,763,000.00
6,717,000.00
6,552,000.00
5,893,000.00
7,264,000.00
--
Normalized Income
3,763,000.00
6,717,000.00
6,552,000.00
7,215,895.00
7,264,000.00
--
Interest Income
--
--
--
--
256,000.00
753,000.00
Interest Expense
3,156,000.00
2,875,000.00
1,406,000.00
1,197,000.00
1,262,000.00
--
Net Interest Income
-3,156,000.00
-2,875,000.00
-1,406,000.00
-1,197,000.00
-1,262,000.00
--
EBIT
7,501,000.00
10,730,000.00
8,752,000.00
7,898,000.00
9,395,000.00
--
EBITDA
12,071,000.00
14,801,000.00
12,169,000.00
11,296,000.00
12,996,000.00
--
Reconciled Cost of Revenue
9,931,000.00
8,451,000.00
6,406,000.00
6,454,000.00
6,159,000.00
--
Reconciled Depreciation
4,570,000.00
4,071,000.00
3,417,000.00
3,398,000.00
3,601,000.00
--
Net Income from Continuing Operation Net Minority Interest
3,763,000.00
6,717,000.00
6,552,000.00
5,893,000.00
7,264,000.00
--
Total Unusual Items Excluding Goodwill
--
--
--
-1,505,000.00
--
--
Total Unusual Items
--
--
--
-1,505,000.00
--
--
Normalized EBITDA
12,071,000.00
14,801,000.00
12,169,000.00
12,801,000.00
12,996,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
--
--
--
-182,105.00
--
--
12/31/2019 - 6/17/1983

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRK Merck & Co., Inc.
126.09
-2.63%
 
ABBV AbbVie Inc.
155.34
-1.10%
 
GILD Gilead Sciences, Inc.
63.94
-2.65%
 
BIIB Biogen Inc.
218.73
+0.42%
 
LLY Eli Lilly and Company
807.86
+0.05%
 
BMY Bristol-Myers Squibb Company
40.49
-1.82%
 
JNJ Johnson & Johnson
144.38
-1.76%
 
AZN AstraZeneca PLC
76.62
-2.44%
 
NVS Novartis AG
99.68
-0.85%
 
PFE Pfizer Inc.
28.30
-2.01%